IP Verse

Blood-Based Biomarkers Of Tumor Sensitivity To Pd-1 Antagonists

Patent No. EP3283882 (titled "Blood-Based Biomarkers Of Tumor Sensitivity To Pd-1 Antagonists") was filed by Merck Sharp & Dohme on Apr 12, 2016. The application was issued on Oct 16, 2024.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
SYMBIOSISSep 15, 2021SYMBIOSIS

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3283882

MERCK SHARP & DOHME
Application Number
EP16780526A
Filing Date
Apr 12, 2016
Status
Patent Maintained As Amended
Sep 13, 2024
Publication Date
Oct 16, 2024
External Links
Slate, Register , Google Patents